ClinicalTrials.gg
CompletedNCT07479745Updated Aug 12, 2026

Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019

A Phase 1 interventional study of [14C]GRT6019 in Healthy Male Volunteers, sponsored by Grünenthal GmbH. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

The main purpose of this study is to determine the mass balance recovery and the metabolite profile of a single dose of carbon-14 ([14C]) GRT6019

Read the detailed description

This is an open-label, non-randomized, single-dose study in healthy male participants. It is planned to enroll a total of ten participants to ensure data in a minimum of six participants. The estimated time for duration of study will be up to 11 weeks.

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers
  2. Aged 30 to 65 years inclusive at the time of signing

Exclusion criteria

Exclusion Criteria:

  1. Serious adverse reaction or serious to any drug or formulation
  2. Presence or history of allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
  3. Presence or history of diseases or conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs
  4. History of clinically significant cardiovascular, renal, hepatic, respiratory, particularly gastrointestinal (GI) disease, especially peptic ulceration, clinically significant GI bleeding, ulcerative colitis, Crohn's disease or irritable bowel syndrome, neurological or psychiatric disorder, or clinically significant dermatological disorder
  5. History of GI surgery (with the exception of appendectomy or hernia repair unless it was performed within the previous 12 months)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    [14C]GRT6019

    Participants will be dosed on the morning of Day 1 following an overnight fast of a minimum of 8 h.

    Drug: [14C]GRT6019

Interventions

  • Single administration in a single dosing period.

    Also known as: Tegacorat, GRM-01, GRT6019

06

What researchers measure

Primary outcomes

  1. Cumulative amount of total radioactivity excreted (CumAe)

    To determine the mass balance recovery of total radioactivity in all excreta (urine and faeces) after a single dose of \[14C\]GRT6019

    Time frame: Day -1 (Admission), Day 1 up to Days 47-48.

  2. Cumulative amount of total radioactivity excreted expressed as a percentage of the radioactive dose administered (Cum%Ae)

    To determine the mass balance recovery of total radioactivity in all excreta (urine and faeces) after a single dose of \[14C\]GRT6019

    Time frame: Day -1 (Admission), Day 1 up to Days 47-48.

  3. Metabolite profling and structural identification

    To perform metabolite profiling, structural identification, and quantification analysis from plasma, urine and faecal samples

    Time frame: Day -1 (Admission), Day 1 up to Days 47-48.

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Jun 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
Mar 25, 2026
Primary completionActual
Jun 18, 2026
CompletionActual
Jun 18, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07479745
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 25, 2026
Primary completion
Jun 18, 2026
Completion
Jun 18, 2026
Last update
Aug 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegacorat

Start the discussion